www.idosr.org
©IDOSR PUBLICATIONS
Abner, 2025
ISSN: 2579-0730
International Digital Organization for Scientific Research IDOSR JBCP/25/101.242900
IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY 10(1):24-29, 2025.
https://doi.org/10.59298/IDOSR/JBCP/25/101.242900

Plant-Based Compounds in the Management of Metabolic Syndrome: A Review

Abner Tom Kalukusu

Department of Clinical Medicine and Dentistry Kampala International University Uganda
Email: abnertomkalukusu@studwc.kiu.ac.ug

ABSTRACT

Metabolic syndrome (MetS) is a group of interrelated risk factors, including central obesity, insulin resistance, dyslipidemia, and hypertension that increase the risk of developing cardiovascular diseases, type 2 diabetes, and other chronic conditions. The global prevalence of MetS has been steadily rising, largely driven by sedentary lifestyles and poor dietary habits. While conventional pharmacological treatments are essential for managing MetS, there is growing interest in plant-based compounds as potential therapeutic agents. These compounds offer promising benefits due to their ability to address multiple aspects of MetS, including inflammation, oxidative stress, insulin resistance, and lipid metabolism, with minimal side effects. This review provides an overview of several plant-based compounds, such as curcumin, resveratrol, berberine, green tea catechins, and cinnamon, highlighting their mechanisms of action, clinical evidence supporting their use, and potential for future treatment options. By exploring the efficacy of these natural compounds, this review aims to contribute to the understanding of alternative and complementary approaches in managing MetS, with a focus on their therapeutic potential, safety, and clinical applicability.

Keywords: Metabolic syndrome, Plant-based compounds, Insulin resistance, Inflammation, Therapeutic agents

INTRODUCTION

Metabolic syndrome (MetS) is a cluster of interconnected risk factors that significantly increase the likelihood of developing chronic conditions such as cardiovascular diseases (CVD), type 2 diabetes (T2D), and other related health issues [1]. The key features of MetS include central obesity, insulin resistance, dyslipidemia (elevated triglycerides and low HDL cholesterol), and hypertension. According to the World Health Organization (WHO), approximately 25% of the global population is affected by MetS, with its prevalence steadily rising due to the increasing adoption of sedentary lifestyles, poor dietary habits, and lack of physical activity [3]. Visceral obesity is often central to the development of MetS, as the accumulation of fat in the abdominal area exacerbates the condition by triggering chronic low-grade inflammation and insulin resistance, which are key contributors to its progression [4,5].

Pharmacological interventions, including statins, antihypertensive drugs, and insulin sensitizers, are commonly prescribed to manage the symptoms of MetS [6]. However, these treatments often come with side effects and do not address the underlying causes of the syndrome. As a result, there is growing interest in exploring alternative treatment options, particularly those derived from plant-based compounds [7]. These compounds have shown promise in combating MetS by offering a variety of beneficial effects, including anti-inflammatory, antioxidant, hypoglycemic, and lipid-lowering actions. Such natural therapies provide a complementary approach to traditional treatments, offering a safer and more holistic strategy for managing MetS [8-10]. This review examines several plant-based compounds with demonstrated efficacy in addressing the key components of MetS, their mechanisms of action, clinical evidence supporting their use, and their potential for future applications in MetS management.

Mechanisms of Action of Plant-Based Compounds in Metabolic Syndrome

Plant-based compounds exert a wide range of effects that can aid in managing the individual components of metabolic syndrome (MetS) [11]. These

compounds influence key metabolic pathways and offer therapeutic potential through their anti-inflammatory, antioxidant, and insulin-sensitizing effects, among others [12]. Below are some of the most important mechanisms through which plant-based compounds exert their beneficial effects in MetS management.

Anti-inflammatory effects: Chronic low-grade inflammation is a key driver of insulin resistance, dyslipidemia, and hypertension, all of which are components of MetS [13]. Many plant compounds possess potent anti-inflammatory properties that help modulate inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins, thereby reducing systemic inflammation [14]. This modulation can not only improve insulin sensitivity but also mitigate other risk factors associated with MetS, including high blood pressure and lipid imbalances. The anti-inflammatory action is particularly significant because inflammation contributes to the development of atherosclerosis and endothelial dysfunction, both of which are risk factors for cardiovascular disease in individuals with MetS [15].

Antioxidant effects: Oxidative stress is another major contributor to the pathogenesis of MetS, leading to cellular damage, particularly in the liver, adipose tissue, and blood vessels [16]. Plant-based compounds with antioxidant properties neutralize reactive oxygen species (ROS), reducing oxidative damage to tissues and organs. This effect can help improve insulin sensitivity and reduce the risk of complications like cardiovascular diseases [17]. Furthermore, antioxidant compounds also protect against the progression of fatty liver disease, a common comorbidity in MetS.

Insulin sensitization: Insulin resistance is a central feature of MetS and plays a pivotal role in the pathophysiology of the syndrome. Improving insulin sensitivity is, therefore, crucial in managing the condition [16]. Several plant compounds have been shown to activate critical signaling pathways, such as AMP-activated protein kinase (AMPK), which improves glucose uptake in cells and enhances insulin sensitivity [15]. By modulating these pathways, plant compounds help to restore normal insulin signaling, thereby addressing one of the root causes of MetS.

Lipid-lowering effects: Dyslipidemia, characterized by high triglycerides and low HDL cholesterol, is a hallmark of MetS [18]. Plant-based compounds can regulate lipid metabolism through various mechanisms, such as enhancing lipoprotein lipase activity, increasing the synthesis of high-density lipoprotein (HDL) cholesterol, and reducing the synthesis of low-density lipoprotein (LDL) cholesterol [19]. By improving lipid profiles, these compounds help reduce the risk of atherosclerosis and cardiovascular disease, which are common complications associated with MetS.

Plant-Based Compounds in the Management of Metabolic Syndrome

A growing body of research supports the potential of plant-based compounds in managing MetS. Many of these compounds are derived from commonly consumed plants and have demonstrated efficacy in clinical studies [20]. Below are some of the most extensively studied plant-based compounds with promising therapeutic effects in MetS:

Curcumin (Curcuma longa)

Curcumin, the active compound found in turmeric, has garnered significant attention due to its potent anti-inflammatory, antioxidant, and insulin-sensitizing properties [21]. Clinical studies have demonstrated that curcumin supplementation can reduce inflammation and oxidative stress, which contribute to the progression of MetS [22]. Additionally, curcumin has been shown to improve insulin sensitivity, reduce blood glucose levels, and lower triglycerides and LDL cholesterol. Several clinical trials have also reported beneficial effects on metabolic markers such as waist circumference, blood pressure, and lipid profiles [23,24]. The compound's ability to modulate inflammatory pathways like NF-κB and inhibit oxidative stress helps address multiple components of MetS simultaneously, making it a promising candidate for MetS management.

Resveratrol (Vitis vinifera)

Resveratrol, a polyphenolic compound found in red wine, grapes, and certain berries, is well-known for its antioxidant and anti-inflammatory effects [25]. These properties make resveratrol a valuable compound in the management of MetS. Studies have shown that resveratrol improves insulin sensitivity, reduces blood glucose levels, and lowers triglyceride levels, all of which are key features of MetS. In addition to its metabolic effects, resveratrol has vasodilatory effects, which help reduce blood pressure, and it improves endothelial function, which is crucial for cardiovascular health [26]. Clinical trials have demonstrated resveratrol's ability to reduce biomarkers of MetS, including waist circumference and blood pressure, further supporting its potential in MetS management.

Berberine (Berberis spp.)

Berberine, an alkaloid compound found in several plant species such as Goldenseal and Berberis, has been extensively studied for its metabolic benefits [27]. It has been shown to activate AMPK, a key regulator of cellular energy metabolism, which helps improve insulin sensitivity and modulate lipid metabolism [28]. Numerous clinical studies have

demonstrated that berberine supplementation effectively lowers fasting blood glucose, HbA1c, triglycerides, and LDL cholesterol levels [29]. Furthermore, berberine has been shown to help reduce body weight and reduce systemic inflammation, both of which are important aspects of MetS. Its multi-targeted actions make berberine a strong candidate for addressing the underlying causes of MetS.

Green Tea Catechins (Camellia sinensis)

Green tea is rich in polyphenolic compounds known as catechins, particularly epigallocatechin gallate (EGCG), which exhibit antioxidant and anti-inflammatory effects [30]. Green tea catechins have been shown to improve insulin sensitivity, lower blood glucose levels, and reduce body fat, making them effective in managing MetS. Furthermore, these catechins have lipid-lowering properties, helping to reduce triglyceride and LDL cholesterol levels while increasing HDL cholesterol [31]. Several studies have demonstrated that green tea catechins contribute to weight management, improve metabolic function, and reduce the risk of developing type 2 diabetes and cardiovascular disease in individuals with MetS [30]. Green tea's ability to target multiple components of MetS further underscores its therapeutic potential.

Cinnamon (Cinnamomum verum)

Cinnamon, particularly its active compound cinnamaldehyde, has been found to have insulin-sensitizing effects and may help regulate blood glucose levels [32]. Cinnamon supplementation has been linked to improved fasting blood glucose levels, reduced HbA1c levels, and enhanced insulin sensitivity in individuals with MetS [33]. Additionally, cinnamon has been shown to reduce triglyceride and LDL cholesterol levels. The anti-inflammatory and antioxidant properties of cinnamon contribute to its overall effectiveness in managing MetS [34]. Given its accessibility and low cost, cinnamon offers a viable option for individuals seeking complementary treatments for MetS, particularly in improving glycemic control and lipid profiles.

Plant-based compounds offer a promising alternative or adjunct to traditional pharmacological treatments for MetS [35]. With their multifaceted mechanisms of action, including anti-inflammatory, antioxidant, insulin-sensitizing, and lipid-lowering effects, these compounds have the potential to address the key components of MetS simultaneously [33]. Curcumin, resveratrol, berberine, green tea catechins, and cinnamon are among the most studied plant-based compounds, with substantial clinical evidence supporting their efficacy. Further research is needed to establish optimal dosages, formulations, and combinations of these compounds to maximize their therapeutic benefits in the management of MetS.

Safety and Considerations

While plant-based compounds offer significant potential in managing MetS, it is crucial to assess their safety and possible interactions with other medications. Generally, most plant-based compounds are safe and well-tolerated when consumed in moderate amounts [36]. However, the bioavailability of many plant compounds can be a limiting factor, which may reduce their effectiveness. To overcome this challenge, enhanced formulations such as nanoparticles, liposomal preparations, or co-administration with substances like piperine (found in black pepper) are sometimes used to improve absorption and bioavailability 37]. Despite their beneficial properties, plant compounds can interact with various medications, including anticoagulants, antihypertensive drugs, and insulin-sensitizing agents [38]. For example, compounds like curcumin and resveratrol may have blood-thinning effects, which can enhance the effects of anticoagulants, increasing the risk of bleeding [39]. Similarly, some plant compounds may interact with medications that regulate blood pressure or glucose levels, potentially leading to additive or synergistic effects [40]. Therefore, it is essential for individuals considering plant-based compounds as adjunctive treatments for MetS to consult healthcare professionals before starting supplementation. This helps ensure that there are no adverse interactions or contraindications with other medications they may be taking.

CONCLUSION

Plant-based compounds hold considerable promise in managing MetS by addressing key components such as insulin resistance, dyslipidemia, hypertension, and obesity [41]. While several of these compounds have shown positive effects in clinical trials, additional large-scale, well-designed studies are needed to confirm their efficacy and safety across diverse populations [42]. Future research should focus on determining the optimal dosages, potential combinations of plant compounds, and their long-term effects. Additionally, investigating the mechanisms through which these compounds influence metabolic pathways will provide deeper insights into their therapeutic potential. The role of plant compounds in gut microbiota modulation and epigenetic regulation presents another exciting avenue for future research. Understanding these mechanisms may help identify new targets for MetS treatment and enhance the effectiveness of plant-based therapies [43]. Ultimately, plant-based compounds may serve as valuable adjuncts to traditional pharmacological treatments, offering a

more natural and holistic approach to managing MetS. With continued research, these compounds could become an integral part of comprehensive MetS management strategies.

REFERENCES

1. Zhang Y, Liu S, Li Y, Wang J, Liu Y, Zhang Y. Celastrol ameliorates obesity through enhancing IL1R1-mediated thermogenesis in POMC neurons. Cell Metab. 2018; 27(5):1121-1133.e5.
2. Gamboa-Gómez CI, Rocha-Guzmán NE, Gallegos-Infante JA, Moreno-Jiménez MR, Vázquez-Cabral BD, González-Laredo RF. Plants with potential use on obesity and its complications. EXCLI J. 2015; 14:809-831.
3. Subías-Perié J, Navarrete-Villanueva D, Fernández-García ÁI, Moradell A, Gesteiro E, Pérez-Gómez J, Ara I, Vicente-Rodríguez G, Casajús JA, Gómez-Cabello A. Prevalence of Metabolic Syndrome and Association with Physical Activity and Frailty Status in Spanish Older Adults with Decreased Functional Capacity: A Cross-Sectional Study. Nutrients. 2022: 14(11):2302. doi: 10.3390/nu14112302. PMID: 35684102; PMCID: PMC9182809.
4. Zhou Y, Zheng J, Li Y, Xu DP, Li S, Chen YM, et al. Natural polyphenols for prevention and treatment of cancer. Nutrients. 2016; 8(8):515.
5. Huang W, Yan Z, Li D, Ma Y, Zhou J. Saponins isolated from Dioscorea opposita Thunb. leaves alleviated insulin resistance via AMPK/ACC signaling pathway. Biomed Pharmacother. 2018; 108:1535-1544.
6. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012; 7(9):e42529.
7. Guo X, Zhang X, Wang X, Zhang J, Wang J, Li G, et al. Chlorogenic acid protects against high-fat diet-induced obesity and insulin resistance in mice. Pharmacol Res. 2019; 144:1-9.
8. Zhao L, Zhang Q, Ma W, Tian F, Shen H, Zhou M. Anti-obesity mechanism of the water extract of Pu-erh tea by improving the lipid metabolism and modulating the gut microbiota in high-fat diet-fed mice. Food Funct. 2019; 10(5):2235-2249.
9. Zhou Y, Zheng J, Li S, Zhou T, Zhang P, Li HB. Effects and mechanisms of anthocyanins on cardiovascular diseases. Adv Nutr. 2019;10(4):452-460.
10. Zhang X, Zhu X, Sun Y, Hu B, Hou T, Li W, et al. Geniposide inhibits hepatic gluconeogenesis and increases liver glycogen synthesis via AMPK activation. Biochem Biophys Res Commun. 2016; 478(1):362-368.
11. Wiśniewska K, Okręglicka KM, Nitsch-Osuch A, Oczkowski M. Plant-Based Diets and Metabolic Syndrome Components: The Questions That Still Need to Be Answered-A Narrative Review. Nutrients. 2024: 16(1):165. doi: 10.3390/nu16010165. PMID: 38201994; PMCID: PMC10780839.
12. De, B., Bhandari, K., Katakam, P. *et al.* Development of a standardized combined plant extract containing nutraceutical formulation ameliorating metabolic syndrome components. *SN Appl. Sci.* 2019; **1**, 1484. https://doi.org/10.1007/s42452-019-1518-9
13. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017 Aug;11(8):215-225. doi: 10.1177/1753944717711379. Epub 2017 Jun 22. PMID: 28639538; PMCID: PMC5933580.
14. Kassi, E., Pervanidou, P., Kaltsas, G. *et al.* Metabolic syndrome: definitions and controversies. *BMC Med* 2011; **9**, 48. https://doi.org/10.1186/1741-7015-9-48
15. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag. 2006;2(2):145-52. doi: 10.2147/vhrm.2006.2.2.145. PMID: 17319458; PMCID: PMC1993992.
16. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int J Mol Sci. 2023; 24(9):7898. doi: 10.3390/ijms24097898. PMID: 37175603; PMCID: PMC10178199.
17. Sharebiani H, Mokaram M, Mirghani M, Fazeli B, Stanek A. The Effects of Antioxidant Supplementation on the Pathologic Mechanisms of Metabolic Syndrome and Cardiovascular Disease Development. Nutrients. 2024 May 27;16(11):1641. doi: 10.3390/nu16111641. PMID: 38892574; PMCID: PMC11175159.
18. Świątkiewicz I, Wróblewski M, Nuszkiewicz J, Sutkowy P, Wróblewska J, Woźniak A. The Role of Oxidative Stress Enhanced by

Adiposity in Cardiometabolic Diseases. *International Journal of Molecular Sciences.* 2023; 24(7):6382. https://doi.org/10.3390/ijms24076382

19. Alan Chait, Robert H. Eckel, Michal Vrablik, Alberto Zambon, Lipid-lowering in diabetes: An update, Atherosclerosis, 2024; 394, 117313. https://doi.org/10.1016/j.atherosclerosis.2023.117313.
20. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017; 11(8):215-225. doi: 10.1177/1753944717711379. Epub 2017 Jun 22. PMID: 28639538; PMCID: PMC5933580.
21. Zhang Y, Liu S, Li Y, Wang J, Liu Y, Zhang Y. Celastrol ameliorates obesity through enhancing IL1R1-mediated thermogenesis in POMC neurons. Cell Metab. 2018; 27(5):1121-1133.e5.
22. Gamboa-Gómez CI, Rocha-Guzmán NE, Gallegos-Infante JA, Moreno-Jiménez MR, Vázquez-Cabral BD, González-Laredo RF. Plants with potential use on obesity and its complications. EXCLI J. 2015; 14:809-831.
23. Su Y, Sun J, Zhou Y, Sun W. The Relationship of Waist Circumference with the Morbidity of Cardiovascular Diseases and All-Cause Mortality in Metabolically Healthy Individuals: A Population-Based Cohort Study. Rev Cardiovasc Med. 2024; 25(6):212. doi: 10.31083/j.rcm2506212. PMID: 39076338; PMCID: PMC11270058.
24. Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, Fokou PVT, Martins N, Sharifi-Rad J. Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines. 2018; 6(3):91. doi: 10.3390/biomedicines6030091. PMID: 30205595; PMCID: PMC6164842.
25. Farhan M, Rizvi A. The Pharmacological Properties of Red Grape Polyphenol Resveratrol: Clinical Trials and Obstacles in Drug Development. Nutrients. 2023; 15(20):4486. doi: 10.3390/nu15204486. PMID: 37892561; PMCID: PMC10610408.
26. Utami AR, Maksum IP, Deawati Y. Berberine and Its Study as an Antidiabetic Compound. Biology (Basel). 2023; 12(7):973. doi: 10.3390/biology12070973. PMID: 37508403; PMCID: PMC10376565.
27. Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI, Crişan G, Buzoianu AD. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front Pharmacol. 2018; 9:557. doi: 10.3389/fphar.2018.00557. PMID: 30186157; PMCID: PMC6111450.
28. Salehi B, Selamoglu Z, Sener B, Kilic M, Kumar Jugran A, de Tommasi N, Sinisgalli C, Milella L, Rajkovic J, Flaviana B. Morais-Braga M, et al. *Berberis* Plants—Drifting from Farm to Food Applications, Phytotherapy, and Phytopharmacology. *Foods.* 2019; 8(10):522. https://doi.org/10.3390/foods8100522
29. Mokra D, Joskova M, Mokry J. Therapeutic Effects of Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis. Int J Mol Sci. 2022; 24(1):340. doi: 10.3390/ijms24010340. PMID: 36613784; PMCID: PMC9820274.
30. Musial C, Kuban-Jankowska A, Gorska-Ponikowska M. Beneficial Properties of Green Tea Catechins. Int J Mol Sci. 2020; 21(5):1744. doi: 10.3390/ijms21051744. PMID: 32143309; PMCID: PMC7084675.
31. Qin B, Panickar KS, Anderson RA. Cinnamon: potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes. J Diabetes Sci Technol. 2010; 4(3):685-93. doi: 10.1177/193229681000400324. PMID: 20513336; PMCID: PMC2901047.
32. Silva ML, Bernardo MA, Singh J, de Mesquita MF. Cinnamon as a Complementary Therapeutic Approach for Dysglycemia and Dyslipidemia Control in Type 2 Diabetes Mellitus and Its Molecular Mechanism of Action: A Review. Nutrients. 2022; 14(13):2773. doi: 10.3390/nu14132773. PMID: 35807953; PMCID: PMC9269353.
33. Mohsin SN, Saleem F, Humayun A, Tanweer A, Muddassir A. Prospective Nutraceutical Effects of Cinnamon Derivatives Against Insulin Resistance in Type II Diabetes Mellitus—Evidence From the Literature. Dose-Response. 2023; 21(3). doi:10.1177/15593258231200527
34. Medagama, A.B. The glycaemic outcomes of Cinnamon, a review of the experimental evidence and clinical trials. *Nutr. J* **14**, 108. https://doi.org/10.1186/s12937-015-0098-9.

35. Wiśniewska K, Okręglicka KM, Nitsch-Osuch A, Oczkowski M. Plant-Based Diets and Metabolic Syndrome Components: The Questions That Still Need to Be Answered-A Narrative Review. Nutrients. 2024; 16(1):165. doi: 10.3390/nu16010165. PMID: 38201994; PMCID: PMC10780839.
36. Noce A, Di Lauro M, Di Daniele F, Pietroboni Zaitseva A, Marrone G, Borboni P, Di Daniele N. Natural Bioactive Compounds Useful in Clinical Management of Metabolic Syndrome. Nutrients. 2021; 13(2):630. doi: 10.3390/nu13020630. PMID: 33669163; PMCID: PMC7919668.
37. Łuszczki E, Boakye F, Zielińska M, Dereń K, Bartosiewicz A, Oleksy Ł, Stolarczyk A. Vegan diet: nutritional components, implementation, and effects on adults' health. Front Nutr. 2023; 10:1294497. doi: 10.3389/fnut.2023.1294497. Erratum in: Front Nutr. 2024; 10:1354336. doi: 10.3389/fnut.2023.1354336. PMID: 38024367; PMCID: PMC10665534.
38. Zarantonello D, Brunori G. The Role of Plant-Based Diets in Preventing and Mitigating Chronic Kidney Disease: More Light than Shadows. J Clin Med. 2023; 12(19):6137. doi: 10.3390/jcm12196137. PMID: 37834781; PMCID: PMC10573653.
39. Kim DC, Ku SK, Bae JS. Anticoagulant activities of curcumin and its derivative. BMB Rep. 2012; 45(4):221-6. doi: 10.5483/bmbrep.2012.45.4.221. PMID: 22531131.
40. Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, Fokou PVT, Martins N, Sharifi-Rad J. Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines. 2018; 6(3):91. doi: 10.3390/biomedicines6030091. PMID: 30205595; PMCID: PMC6164842.
41. Crowe-White KM, Evans LW, Kuhnle GG, Milenkovic D, Stote K. Flavan-3-ols and cardiometabolic health: First ever dietary bioactive guideline. Adv Nutr. 2022; 13(5):1231-1252.
42. Torres-Saavedra PA, Winter KA. An Overview of Phase 2 Clinical Trial Designs. Int J Radiat Oncol Biol Phys. 2022; 112(1):22-29.doi: 10.1016/j.ijrobp.2021.07.1700. Epub 2021 Aug 4. PMID: 34363901; PMCID: PMC8688307.

CITE AS: Abner Tom Kalukusu (2025). Plant-Based Compounds in the Management of Metabolic Syndrome: A Review. IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY 10(1):24-29. https://doi.org/10.59298/IDOSR/JBCP/25/101.242900